Efficacy and safety of fosfomycin plus imipenem versus vancomycin for complicated bacteraemia and endocarditis due to methicillin-resistant Staphylococcus aureus: a randomized clinical trial

J M Pericàs; A Moreno; M Almela; C García-de-la-Mària; F Marco; P Muñoz; C Peña; A de Alarcón; A Del Río; A Eworo; A Cruceta; J C Paré; C A Mestres; J M Miró; FOSIMI Investigators

doi:10.1016/j.cmi.2018.01.010

Efficacy and safety of fosfomycin plus imipenem versus vancomycin for complicated bacteraemia and endocarditis due to methicillin-resistant Staphylococcus aureus: a randomized clinical trial

Clin Microbiol Infect. 2018 Jun;24(6):673-676. doi: 10.1016/j.cmi.2018.01.010. Epub 2018 Feb 3.

Authors

J M Pericàs¹, A Moreno², M Almela³, C García-de-la-Mària¹, F Marco³, P Muñoz⁴, C Peña⁵, A de Alarcón⁶, A Del Río¹, A Eworo⁴, A Cruceta⁷, J C Paré⁸, C A Mestres⁹, J M Miró¹⁰; FOSIMI Investigators

Collaborators

FOSIMI Investigators:
José M Miró¹¹, Asunción Moreno¹¹, Juan M Pericàs¹¹, Juan Ambrosioni¹¹, Adrián Tellez¹¹, Marta Hernandez-Meneses¹¹, Ana Del Río¹¹, Carlos Cervera¹¹, Francesc Marco¹¹, Cristina Garcia de la Mària¹¹, Yolanda Armero¹¹, Manel Almela¹¹, Carlos A Mestres¹¹, Juan C Paré¹¹, David Fuster¹¹, Ramón Cartañá¹¹, Salvador Ninot¹¹, Manel Azqueta¹¹, Marta Sitges¹¹, Jose Ramírez¹¹, Merce Brunet¹¹, Dolors Soy¹¹, Jaume Llopis¹¹, Carmen Peña¹², Oriol Gasch¹², Cristina Suarez¹², Miquel Pujol¹², Javier Ariza¹², Jordi Carratalà¹², Francisco Gudiol¹², Patricia Muñoz⁴, Alia Eworo⁴, Emilio Bouza⁴, Arístides de Alarcón¹³, Mercè Gurgui¹⁴, Natividad Benito¹⁴, Juan-Emilio Losa-Garcia¹⁵, Enrique Navas¹⁶, Jose R Paño-Pardo¹⁷, Belén Loeches¹⁷, Jose R Arribas¹⁷, Miguel Montejo¹⁸, Juan Galvez¹⁹

Affiliations

¹ Infectious Diseases Service, Hospital Clinic, Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
² Infectious Diseases Service, Hospital Clinic, Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain. Electronic address: [email protected].
³ Microbiology Department, Hospital Clinic, Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain; Barcelona Centre for International Health Research (CRESIB), Barcelona, Spain.
⁴ Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain.
⁵ Infectious Diseases Service, Hospital de Bellvitge, IDIBELL, University of Barcelona, L'Hospitalet de Llobregat, Spain.
⁶ Infectious Diseases Service, UGC de Enfermedades Infecciosas, Microbiología y Medicina Preventiva Grupo de Investigacion en Enfermedades Infecciosas, Instituto de Biomedicina de Sevilla (IBiS)/CSIC/HU Virgen del Rocío, Sevilla, Spain.
⁷ Clinical Trials Unit, Hospital Clinic, Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
⁸ Cardiology Department, Hospital Clinic, Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
⁹ Department of Cardiovascular Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
¹⁰ Infectious Diseases Service, Hospital Clinic, Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain. Electronic address: [email protected].
¹¹ Hospital Clínic Endocarditis Study Group, Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain.
¹² Hospital de Bellvitge-IDIBELL, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
¹³ Infectious Diseases Service, UGC de Enfermedades infecciosas, Microbiología y Medicina Preventiva Grupo de Investigacion en Enfermedades Infecciosas, Instituto de Biomedicina de Sevilla (IBiS)/CSIC/HU Virgen del Rocío, Sevilla, Spain.
¹⁴ Hospital de la Santa Creu i Sant Pau and Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Barcelona, Spain.
¹⁵ Fundación Hospital Alcorcón, Madrid, Spain.
¹⁶ Hospital Universitario Ramón y Cajal-IRYCIS, Madrid, Spain.
¹⁷ Hospital Universitario La Paz, Madrid, Spain.
¹⁸ Hospital Universitario Cruces, Bilbao, Spain.
¹⁹ Hospital Universitario Virgen de la Macarena, Sevilla, Spain.

PMID: 29408610
DOI: 10.1016/j.cmi.2018.01.010

No abstract available

Publication types

Case Reports
Letter
Multicenter Study
Randomized Controlled Trial

MeSH terms

Aged
Aged, 80 and over
Anti-Bacterial Agents / administration & dosage
Anti-Bacterial Agents / adverse effects
Anti-Bacterial Agents / therapeutic use*
Bacteremia / complications
Bacteremia / drug therapy*
Endocarditis / complications
Endocarditis / drug therapy*
Endocarditis / microbiology
Female
Fosfomycin / administration & dosage
Fosfomycin / adverse effects
Fosfomycin / therapeutic use*
Humans
Imipenem / administration & dosage
Imipenem / adverse effects
Imipenem / therapeutic use*
Male
Methicillin-Resistant Staphylococcus aureus / drug effects*
Microbial Sensitivity Tests
Middle Aged
Treatment Outcome
Vancomycin / administration & dosage
Vancomycin / adverse effects
Vancomycin / therapeutic use*

Substances

Anti-Bacterial Agents
Fosfomycin
Vancomycin
Imipenem